MYCN and medulloblastoma: For example, resistance to TRAIL-induced apoptosis (24), EGFR and MYCN amplification (25), along with PDGFR activation (26), overexpression of stem-cell markers Oct-4 and Sox-2 (27) and epigenetic deregulation (28) have been reported in medulloblastomas.